Oncologists today now have a much greater understanding of the mutational landscape underlying some tumors. However, in many respects it is still a daunting task-one that may require more effective interpretation tools.
Oncologists today now have a much greater understanding of the mutational landscape underlying some tumors. However, in many respects it is still a daunting task-one that may require more effective interpretation tools.
Now, a new tool is available to all clinicians to help better advance precision medicine in the field of oncology. Researchers at Washington University School of Medicine have developed an online tool to help clinicians improve their chances of identifying important mutations in a patient's tumor and potentially connecting genetic errors with agents known to target them.
The online resource, called CIViC, is described and published online in the January 2017 issue of Nature Genetics. CIViC stands for Clinical Interpretations of Variants in Cancer, and researchers say it is a sort of Wikipedia of cancer genetics. Anyone can create an account and contribute information. That information is curated by editors and moderators who are experts in the field.
“Oncologists trying to interpret the raw data are faced with an overwhelming task of plumbing the literature, reading papers, trying to understand what the latest studies tell them about these mutations and how they may or may not be important,” said senior author Obi L. Griffith, PhD, an assistant professor of medicine at Washington University School of Medicine in St. Louis.
The CIViC knowledgebase is an attempt to solve this problem. This is one of many efforts to collect and interpret such information. However, CIViC is the only one that appears to be entirely open access. Anyone is free to contribute and use the content as well as the source code. Currently, there are no restrictions on its use and it is designed to be a community exercise and a public resource.
Though anyone can submit a new piece of information or suggest edits to existing data, at least two independent contributors must agree that the new information should be incorporated, and one of those users must be an expert editor. Expert editors are not permitted to approve their own submissions. The CIViC website provides details about how new users may be promoted to expert editors and administrators.
To date, the site has seen more than 17,500 users from academic institutions, governmental organizations, and commercial entities from around the world. Since CIViC's launch, 59 users have volunteered their time to contribute their knowledge to CIViC, including descriptions of the clinical relevance of 732 mutations from 285 genes for 203 types of cancer.
Building Efficiency and Scaling With a Remote Genetic Counseling Program
Smita K. Rao, MBBS, MS, et al gave an overview of implementing genetic counseling into oncology practices through telemedicine.
Nurse-Led Program May Increase Germline Testing in Black Veterans With Cancer
June 1st 2023The association between use of a telegenetics service and lower likelihood of germline testing was statistically significant among black veterans with cancer, according to a recent retrospective cohort study.
New NSCLC Treatment Options Needed to Successfully Target Multiple Gene Changes
November 24th 2017Researchers analyzed samples from 1,122 patients with advanced-stage NSCLC and discovered that 92.9% of tumors from harbored multiple changes in cancer-related genes in addition to the EGFR driver mutation.